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Abstract
A number of antibodies have been developed that induce lethal iron deprivation (LID) by targeting
the transferrin receptor 1 (TfR1/CD71) and either neutralizing transferrin (Tf) binding, blocking
internalization of the receptor and/or inducing its degradation. We have developed recombinant
antibodies targeting human TfR1 (ch128.1 and ch128.1Av), which induce receptor degradation
and are cytotoxic to certain malignant B-cells. We now show that internalization of TfR1 bound to
these antibodies can lead to its sequestration and degradation, as well as reduced Tf uptake, and
the induction of a transcriptional response consistent with iron deprivation, which is mediated in
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part by downstream targets of p53. Cells resistant to these antibodies do not sequester and degrade
TfR1 after internalization of the antibody/receptor complex, and accordingly maintain their ability
to internalize Tf. These findings are expected to facilitate the rational design and clinical use of
therapeutic agents targeting iron import via TfR1 in hematopoietic malignancies.
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Introduction
Import of iron into cells is primarily accomplished through the uptake of its carrier protein,
transferrin (Tf), into acidified recycling vesicles via the transferrin receptor 1 (TfR1/CD71)
[1,2]. The subsequent transport of iron from acidified vesicles into the cytoplasm is then
accomplished by the divalent metal transporter 1 (DMT1), while the Tf–TfR complex is
returned to the cell surface [1-4]. In general, TfR1 is required by proliferating cells and is
expressed at high levels in certain malignancies, in some of which it is associated with
disease grade and progression [2,5]. Hematopoietic malignancies express abnormally high
levels of TfR1 to meet their high demand for iron and maintain their rapid rate of
proliferation [2,5]. Accordingly, TfR1 is an attractive target for anti-cancer agents,
particularly those that aim to induce lethal iron deprivation in malignant hematopoietic cells.
A number of therapeutic agents designed to target TfR have been shown to induce lethal
iron deprivation (LID) and/or deliver toxic compounds, pro-drugs or nucleic acids into
malignant cells [3,6-13]. Many of these agents are actively being developed for the
treatment of various malignancies. A variety of antibodies with specificity for human TfR1,
capable of directly inhibiting cell proliferation and/or inducing apoptosis in a number of
malignant hematopoietic cells, have been developed since the early 1980s [2,6,9-12,14].
Anti bodies specific for TfR1 offer a potentially safer and more effective alternative to the
use of pleiotropic iron chelators for the targeted disruption of cellular iron import in
malignant cells. The use of therapeutic antibodies targeting human TfR1 in hematopoietic
malignancies for the induction of LID has advanced greatly in recent years. A number of
these antibodies remain under investigation and are promising candidates for the treatment
of hematopoietic malignancies alone or in combination with other therapies [2,6,10].
Despite the development of promising therapies targeting iron homeostasis, TfR1, and other
hallmarks of cancer in malignant cells, better treatments are urgently needed for incurable
hematopoietic malignancies, such as multiple myeloma and aggressive lymphomas [15], and
could be offered through the design and development of novel targeted therapies.
We developed a mouse/human chimeric antibody with human immunoglobulin 3 (IgG3)
constant regions and the variable regions of a mouse monoclonal antibody specific for
human TfR1 (128.1) [6], previously known as anti-hTfR IgG3 (ch128.1) [14]. We also
developed a fusion protein composed of ch128.1 genetically fused to chicken avidin at its
carboxy terminus, previously known as anti-hTfR IgG3-Av (ch128.1Av) [9,14]. This
antibody–avidin fusion protein exists as a dimer in solution due to the non-covalent
interaction between its avidin moieties, can be used as a delivery vehicle for biotinylated
compounds into cells expressing TfR1, and is intrinsically toxic (anti-proliferative/pro-
apoptotic) to a variety of malignant B cells, including multiple myeloma and lymphoma
cells [9,14,16-18]. The binding of Tf or the hemochromatosis protein (HFE) to TfR1 is not
inhibited by ch128.1 or ch128.1Av, and these antibodies did not cross-react with TfR2
[14,17], a second version of the receptor expressed primarily in hepatocytes and the gut
endothelium [1,2]. ch128.1Av and, to a lesser extent, ch128.1 induce degradation of TfR1 in
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sensitive cells, and their cytotoxic effect is blocked in the presence of iron salts. However,
the mechanism by which these antibodies block iron uptake and induce LID in malignant
hematopoietic cells requires further study, particularly in light of their differential toxicity to
a variety of malignant B-cells expressing high levels of TfR1.
The main goals of the present work are to further investigate the mechanisms of LID
induced in malignant hematopoietic cells by antibodies that bind TfR1 but do not inhibit its
binding to Tf, and to understand the differences between cells that are sensitive and resistant
to treatment with these antibodies. We show that although the internalization of these
antibodies is canonical (both clathrin and dynamin dependent), ch128.1Av and, to a lesser
extent, ch128.1 inhibit the function of TfR1 by inducing its sequestration, which we confirm
is associated with a subsequent degradation of the receptor in sensitive cells. This reduction
in the levels of TfR1 on the cell surface results in decreased Tf uptake, and the induction of
LID in malignant hematopoietic B-cells, which is mediated in part by downstream targets of
p53. We also describe cellular phenotypes associated with resistance to treatment with these
antibodies. These studies are expected to aid in the future design of therapeutic agents aimed
at exploiting iron homeostasis for the treatment of incurable B-cell malignancies through the
targeting of TfR1.
Materials and methods
Cells and reagents
The Epstein–Barr virus (EBV) positive human B-lymphoblastoid cell lines IM-9 and
ARH-77, and the plasmacytoid cell line U266, isolated from a patient with multiple
myeloma, were purchased from the American Type Culture Collection (ATCC, Manassas,
VA). Cells derived from a patient with Burkitt lymphoma and positive for EBV (Akata +)
were a kind gift from Dr. Richard Ambinder (Johns Hopkins School of Medicine), while the
isogenic B-lymphoblastoid cell lines TK6 (p53 wild type) and NH32 (p53 mutant at codon
237 of exon 7) [19], differing in their expression of the p53 protein, were kind gifts of Drs.
Daniel H. Appella and Ana I. Robles (National Institutes of Health). All cell lines were
maintained in standard tissue culture conditions, RPMI 1640 supplemented with 10% fetal
bovine serum and penicillin/streptomycin, as previously described [16,18,20]. Tf-Alexa®
(excitation 488 nm), CMPTX® (excitation 596 nm) and Zenon® (excitation 596 nm) were
obtained from Life Technologies (Carlsbad, CA), calcein and the iron chelator
desferrioxamine (DFO) from Sigma-Aldrich Corp. (St. Louis, MO) and the dynamin
inhibitor Dynasore® from Tocris Biosciences (Ellsville, MO). The cell-permeable iron
chelator salicylaldehyde isonicotinoyl hydrazone (SIH) was a kind gift of Dr. Prem Ponka
(McGill University) [21], and the antibodies ch128.1 and ch128.1Av were produced and
purified as previously described [9,14].
Cell proliferation and viability assays
IM-9 and U266 cells were incubated with 10 nM ch128.1Av, 10 nM ch128.1, 50 μM DFO
or buffer in tissue culture conditions for 24 h or 48 h in 24- or 96-well plates. In proliferation
assays based on [3H]-thymidine incorporation, 16 h prior to the end of each time point, an
aliquot of cells treated with each agent was removed from 24-well plates and seeded in a
new 96-well plate to evaluate the inhibition of proliferation by the [3H]-thymidine
incorporation assay, as previously described [16]. Cell viability WST-1 assays (Hoffmann-
La Roche Ltd, Basel, Switzerland) were conducted according to the manufacturer’s
instructions in 96-well plates, at least in triplicate, and their colorimetric readings obtained
using a DTX880 Multimode Detector (Beckman Coulter Inc., Brea, CA). Experiments were
repeated at least twice. Data from treatment conditions were normalized to values obtained
from control cells.
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Confocal microscopy of Tf uptake in vitro
Cells labeled with the live cell tracker CMPTX®, according to the manufacturer’s
instructions, were treated with Tf-Alexa® at a concentration of 50 μg/mL in serum-free
medium for 30 min at 37 °C. Alternatively, unlabeled cells were incubated with 10 nM of
ch128.1 or ch128.1Av bound to Zenon® as indicated by the manufacturer for 1 h or 6 h. All
cells were then washed and incubated with fluorescent Tf as described above. Cells were
washed, fixed with 2% paraformaldehyde, mounted on slides in 100% glycerol and imaged
using a confocal microscope (Carl Zeiss, Inc., Oberkochen, Germany) equipped with an oil-
immersion NA 1.4 60× objective and saved after a 2 × digital enhancement, or using an
open perfusion chamber (volume 200 μL) on a Nikon Diaphot microscope coupled to a
custom confocal imaging system, as previously described [22]. Briefly, excitation from a
475 nm diode laser was delivered via scanning mirrors to the specimen through a 60 × lens.
Fluorescence emission was gathered through a dichroic mirror and 535 bandpass filter to a
photomultiplier tube (Hamamatsu, Bridgewater, NJ), and images were acquired at four
frames per minute by an image acquisition board (Bitflow Raven) controlled by Video
Savant software with a maximum image resolution of 980 × 730 pixels. Experiments were
repeated at least twice.
Inhibition of Tf and/or antibody uptake
Cells were incubated for 30 min in the presence of hypertonic sucrose (0.4 M) at 4 °C, or
with increasing concentrations (0-400 μM) of the dynamin inhibitor Dynasore® [23] to
prevent TfR internalization. Cells were then incubated with Tf-Alexa® or Zenon®-bound
antibodies at the concentrations indicated above for 30 min at 37 °C. Experiments were
repeated at least twice. Confocal microscopy images of these cells were obtained as
described in the section above on Tf uptake in vitro.
Inhibition of Tf uptake in vivo
Cells (5 × 106) were labeled with CMPTX® according to the manufacturer’s instructions
and incubated with 50 μg of ch128.1 or ch128.1Av for 30 min at 37 °C and then injected
into the peritoneal cavity of C.B-17 SCID (severe combined immune deficiency)-Beige
mice for 2 h or 48 h. This was performed for three animals per condition for IM-9 and U266
cells during the 48 h incubation experiments, and one animal per condition for all other cells
and treatments. This xenograft model was used given the human nature of the cells and the
fact that the technique has been successfully employed in a number of tumor targeting
studies with other antibodies or chemotherapeutic agents [24,25]. Immediately after
euthanasia, cells were recovered from the peritoneal cavity of the mice by subsequent
washes with 5—10 mL of phosphate buffered saline (PBS). Recovered cells were then
incubated with Tf-Alexa® at a concentration of 50 μg/mL in serum-free medium for 30 min
at 37 °C. Cells were simultaneously kept in vitro at 37 °C for 2 h or 48 h, then washed with
PBS and incubated with Tf-Alexa® alongside the cells recovered from mouse xenografts.
Confocal microscopy images of these cells were then obtained for the 2 h incubations as
described in the section on Tf uptake in vitro; fluorescence intensity of internalized Tf in all
conditions was also analyzed by flow cytometry as described below. Experimental protocols
were approved by the University of California, Los Angeles (UCLA) Institutional Animal
Care and Use Committee (IACUC), and all local and national guidelines on the care of
animals were strictly adhered to. C.B-17 SCID-Beige mice were bred and maintained in the
Defined-Flora Association for Assessment and Accreditation of Laboratory Animal Care-
Accredited Animal Facility of the Department of Radiation Oncology at UCLA.
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Flow cytometry of Tf uptake and cell surface binding
Cells treated with antibodies or buffer (PBS) control for the time shown were washed and
pulse-labeled with Tf-Alexa® as specified above, then washed, fixed and run on a FACScan
cytometer (Becton Dickinson, Franklin Lakes, NJ). In testing competition of Tf with
ch128.1 or ch128.1Av, cells were incubated for 30 min at 4 °C with 100 nM of the
antibodies followed by 1 h incubation with Tf-Alexa® also at 4 °C. Fluorescence associated
with cell surface binding of Tf-Alexa® was then determined. Flow cytometry analysis of
cell viability and apoptosis is discussed in detail in the Supplementary Methods. Analyses of
the distributions of fluorescence intensities collected (channel FL1) of approximately 10,000
cells per condition were conducted using the WinMDI application (version 2.8).
Labile iron pool detection
Cells treated with 10 nM ch128.1Av or 50 μM DFO for 24 h or 48 h were incubated with
100 nM calcein, washed and exposed to an excess (200 μM) SIH [21], as previously
described [26], and this was repeated at least twice. After 20 min, calcein fluorescence was
detected using a DTX880 Multimode Detector (Beckman Coulter) with exitation 480 nm,
emission 530 nm filters.
Immunoblot of whole-cell TfR1 or p53 levels
Whole cell lysates were collected in cell lysis buffer (100 mM Tris-HCl pH 6.8, 4% sodium
dodecyl sulfate [SDS], 10% glycerol) containing complete protease inhibitor cocktail
(Roche Applied Science, Indianapolis, IN), and quantified using the bicinchoninic acid
(BCA) protein assay (Thermo Fischer Scientific, Walnut, CA) as instructed by the
manufacturer. Proteins (25 μg total protein per well) were separated by SDS-polyacrylamide
gel electrophoresis (PAGE) in a 4–12% Bis-Tris NuPage gel (Life Technologies). Proteins
were then transferred to Whatman Protran nitrocellulose membranes (Thermo Fisher
Scientific) and probed with antibodies specific for either human TfR1 (clone H68.4 from
Sigma) or human p53 (produced by Millipore Corp., Billerica, MA); anti-human
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Cell Signaling Technology, Boston,
MA) was used as a loading control according to the manufacturer’s instructions, repeated at
least twice, showing similar results. Digital chemiluminescent images were obtained using
the FluorChem Megapixel High Performance Fluorescence, Chemiluminescence and Visible
Imaging System (Cell Biosciences, Santa Clara, CA). Levels of TfR for three independent
experiments were analyzed and quantified by densitometry analysis.
Microarray hybridization and data quality control
Samples of total mRNA from control or 10 nM ch128.1Av treated IM-9 and U266 cells
collected prior to treatment as well as after 1 h, 3 h, 9 h and 24 h of incubation were
quantified, their integrity evaluated using a Bioanalyzer system (Life Technologies), and
hybridized onto HumanRef-8 v2 Expression BeadChips (Illumina, Inc., San Diego, CA).
Global gene expression profiles for these samples were collected using the BeadArray
software package (Illumina). Quality control, preprocessing and data normalization of whole
genome expression profiles were conducted using the R language for statistical computing
(http://www.r-project.org) and the Lumi [27] package supplied by the Bioconductor Project
(http://www.bioconductor.org) as well as the MATLAB Bioinformatics Toolbox (The
MathWorks, Inc., Natick, MA). This is described in more detail in the Supplementary
Methods, in which we also describe the methods for microarray analysis, data filtering and
in silico transcription factor analysis. Array raw data and associated information are
currently available from the public Gene Expression Omnibus (GEO) database under data
series GSE14754.
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Quantitative polymerase chain reaction
Genes whose expression changed the most after treatment, compared to time-matched
controls, in array data from both sensitive and resistant cells were chosen for validation
using quantitative polymerase chain reaction (PCR). Samples of 5 μg of the mRNA used for
microarray studies at 1 h and 24 h were reverse transcribed using the High Capacity cDNA
Reverse Transcription kit (Applied Biosystems, Carlsbad, CA) according to the
manufacturer’s instructions. Quantitative real-time PCR reactions were performed using an
ABI TaqMan 7900 instrument (Applied Biosystems) with TaqMan® probe sets for β-
glucuronidase (GUSB; housekeeping control), TP53, TFRC, CDKN1A, FDXR, GADD45A,
TP53I3, KLF6 and IL6R in triplicate following the manufacturer’s instructions, repeated
three times.
Transient inhibition of p53 expression using siRNA
IM-9 cells (106) were electroporated with a single pulse of 260 V and a capacitance of 1050
μF with 50 nM siRNA using the Gene Pulser XcellTM (Bio-Rad, Hercules, CA). The p53
siRNA/siAbTM Assay kit (Millipore) was used for these studies according to the
manufacturer’s instructions, repeated at least twice.
Computational and statistical analysis
Fluorescence intensity measurements from confocal microscopy images of cells were
conducted using the National Insitutes of Health (NIH) ImageJ software (rsbweb.nih.gov/ij/)
and analysis code implementing functions from the image processing toolbox of the
MATLAB suite, as discussed in more detail in the Supplementary Methods. Graphs were
generated using Microsoft Excel software (Redmond, WA) in which statistical analyses
including two-tailed Student’s t-tests were also conducted.
Results
TfR1 targeting and antibody induced cytotoxicity
We have previously shown that ch128.1Av and to a lesser extent ch128.1 are cytotoxic to a
variety of malignant hematopoietic cells [14,18], indicated by their reduced viability, lack of
proliferation, and induced apoptosis in response to 72-96 h treatment with this fusion
protein. Of all cells tested, the most sensitive to treatment with ch128.1Av are IM-9 cells,
closely followed by ARH-77. The most resistant cells to ch128.1Av under similar conditions
have been U266 cells. Treatment of sensitive cells with similar concentrations of ch128.1Av
for a period of 48 h induces a significant anti-proliferative/pro-apoptotic effect [Fig. 1(A)
and Supplementary Fig. 1]. However, since the present study focuses on early events in the
induction of LID, the majority of our experiments were conducted during the first 24 h of
treatment, during which the loss of cell viability in sensitive cells induced by the fusion
protein is limited, despite their sensitivity at these early times to the iron chelator DFO [Fig.
1(B)]. Consistent with previous observations [14,17], exposure of cells to a high
concentration (100 nM) of ch128.1Av did not prevent the binding of Tf to TfR1 expressed
on their surface [Fig. 1(C)], confirming that ch128.1Av inhibits TfR1 function downstream
of receptor binding at the cell surface. This is consistent with our observation that sensitive
cells (IM-9 and ARH-77) internalized less fluorescently labeled Tf after treatment with
ch128.1Av [Figs. 2(A) and 2(B)]. This effect was observed in sensitive cells as early as 1 h
after treatment [Supplementary Figs. 2(A) and 2(B)] and was time dependent, becoming
more evident after longer (6 h) exposure to ch128.1Av. A similar, although not significant,
effect was observed after treatment in sensitive cells treated with ch128.1 [Fig. 2(B)]. In
contrast, under similar conditions, resistant cells internalized fluorescent Tf at levels
comparable to those of untreated cells [Figs. 2(A) and 2(B)]. The amount of fluorescently
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labeled ch128.1Av or ch128.1 internalized by cells was not generally indicative of their
sensitivity or resistance to treatment [Fig. 2(C) and Supplementary Fig. 2(C)]. However, the
intracellular distribution of the internalized antibodies in sensitive cells suggested their
sequestration within as of yet unidentified subcellular compartments [Fig. 2(A) and
Supplementary Fig. 2(A)]. These results indicate that ch128.1Av acts by reducing the intake
of Tf in a time-dependent manner, without preventing its binding to TfR1.
Inhibition of TfR1 function in xenograft models of hematopoietic malignancies
Given the potent inhibition of TfR1 function and induction of LID by ch128.1Av in
sensitive but not resistant cells in vitro, we explored the consistency of this effect in vivo.
We measured the uptake of fluorescent Tf by cells recovered 2 h or 48 h after injection into
the peritoneal cavity of SCID-Beige mice in the presence of 50 μg ch128.1Av, 50 μg
ch128.1, or buffer alone. Tf uptake was used as a measure of TfR1 function in recovered
cells, analogous to our in vitro measurements in these cells after treatment with ch128.1Av.
Both sensitive and resistant cells extracted from the peritoneal cavity of mice after
engraftment retained the ability to internalize fluorescently labeled Tf, as expected, albeit at
sometimes lower levels than cells maintained in vitro for the equivalent period of time (Fig.
3). Consistent with our in vitro results, IM-9 cells recovered from the peritoneal cavities of
mice treated with ch128.1Av or ch128.1 showed decreased internalization of Tf at 2 h
(Supplementary Fig. 3) or 48 h post-injection (Fig. 3). A similar effect was observed in
ARH-77 cells, but was not significant. In agreement with our in vitro observations, resistant
cells (U266 and Akata+) retained the ability to internalize Tf after treatment with ch128.1Av
or ch128.1 (Fig. 3 and Supplementary Fig. 3).
Effect on TfR1 trafficking and induction of iron deprivation
We next sought to determine whether, upon binding TfR1, internalization of ch128.1Av
(tetravalent) or ch128.1 (bivalent) is dependent on the canonical pathway of clathrin/
dynamin mediated TfR1 internalization. We found that the internalization of Tf and
ch128.1Av bound to TfR1 was both clathrin (Supplementary Fig. 4) and dynamin
(Supplementary Fig. 5) dependent, and was not significantly different between sensitive and
resistant cells, suggesting the pathway of receptor internalization is unchanged by treatment
with ch128.1Av. In light of previous results highlighting the induced degradation of TfR1 by
ch128.1Av in highly sensitive cells [14], we further investigated events downstream of
receptor internalization that might be affected by treatment with ch128.1Av in both sensitive
and resistant cells, such as receptor recycling and degradation. We observed a significant
reduction of whole-cell TfR1 levels, as compared to those of GAPDH, in sensitive cells
(IM-9 and ARH-77) after 12 h treatment with 10 nM ch128.1Av (Fig. 4), and reduced levels
of cell surface TfR1 after 2–6 h treatment of IM-9 cells under similar conditions, determined
by cell surface binding of fluorescent Tf [Supplementary Fig. 6(A)]. The same effect was
not consistently observed and was not significant in the case of ch128.1 under these
conditions (Fig. 4). In contrast, resistant cells such as U266 and Akata+ showed a non-
significant decrease in their levels of TfR1 protein after similar treatment with ch128.1Av
(Fig. 4), and no decrease in the amount of cell surface TfR after similar treatment for 2–6 h
[Supplementary Fig. 6(B)]. Since sensitive cells treated with ch128.1Av showed a reduction
in cell surface TfR1 available for Tf binding as well as degradation of TfR1, we are unable
to distinguish which of these two processes is primarily responsible for the reduction in Tf
uptake. However, it is most likely that both play a significant role. Consistent with the
disparity observed in the inhibition of TfR1 function by ch128.1Av in sensitive and resistant
cells, we observed a significant reduction in the labile iron pool of IM-9 cells after treatment
with ch128.1Av for 24 h and 48 h, but not in U266 cells under similar conditions
[Supplementary Figs. 6(C) and 6(D)]. The labile iron levels of IM-9 and to a lesser extent
U266 cells were both reduced after treatment with DFO under similar conditions
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[Supplementary Figs. 6(C) and 6(D)]. These results suggest that the end-point of TfR1
targeting by ch128.1Av in sensitive cells is iron deprivation induced by a severe reduction in
Tf-bound iron uptake. However, unlike DFO, ch128.1Av does not reduce the labile iron
stores of resistant cells, as it is unable to efficiently sequester and degrade TfR1 in these
cells.
Transcriptional response to iron deprivation induced in sensitive cells
To better understand the events downstream of LID induced by targeting of TfR1 in the
most sensitive and most resistant cells, we investigated the transcriptional events associated
with antibody treatment in vitro. In a time-course comparative study, we observed the
changes in gene expression in IM-9 and U266 cells at 1 h, 3 h, 9 h and 24 h after treatment
with ch128.1Av. Whole-genome expression profiling of IM-9 cells treated with ch128.1Av
showed time-dependent changes in gene expression that were maximal at the 24 h time point
[Figs. 5(A) and 5(D)]. In contrast, no similar trend was detected in U266 cells, whose
changes in gene expression were maximal at 1 h after treatment with ch128.1Av [Figs. 5(A)
and 5(C)]. Genes whose expression increased in IM-9 cells 24 h after treatment included
CDKN1A (encoding p21), GADD45 (encoding the growth arrest and DNA damage
inducible protein 45A), TP53I3 (encoding the p53 inducible protein 3) and FDXR (encoding
the mitochondrial flavoprotein ferredoxin reductase) [Fig. 5(A)]. We hypothesized that
transcriptional changes induced in IM-9 cells at 24 h of treatment with ch128.1Av were a
result of iron deprivation. This was confirmed by the observation that a number of genes
whose expression changed after treatment (Supplementary Table I) have been previously
described to be affected in response to iron deprivation using iron chelating agents such as
DFO, or in response to 48 h treatment with a lower dose (2.5 nM) of ch128.1Av [28-31].
The expression of genes whose mRNA transcripts contain an iron regulatory element (IRE)
motif, including TFRC (TfR1), DMT1, ACO2 (mitochondrial aconitase), and FTL (ferritin
light chain), changed significantly in IM-9 cells treated with ch128.1Av [Fig. 5(B)].
Expression of these genes in U266 cells either did not change or changed inversely after
treatment with ch128.1A [Figs. 5(A) and 5(B)], with the exception of the TfR1 transcript,
whose expression increased after treatment in both IM-9 and U266 cells. These results thus
support the hypothesis that the transcriptional response triggered by ch128.1Av is correlated
to the induction of lethal iron deprivation in sensitive cells.
Cytotoxicty resulting from antibody-induced iron deprivation is p53-associated
A pattern of changes in gene expression similar to that observed in IM-9 cells (p53 wild
type) after treatment with ch128.1Av has also been previously associated with the activity of
the tumor suppressor protein p53 [29]. Genes that changed most notably in IM-9 cells in
response to treatment with ch128.1Av, and are known downstream targets of p53, include
CDKN1A, TP53I3, GADD45 and FDXR. An in silico analysis of transcription factor
binding sites of the promoter regions of genes whose transcript levels changed significantly
in IM-9 cells after treatment was also conducted, and indicated a significant enrichment of
genes in this list with p53 binding sites in their promoter regions (Supplementary Fig. 7). As
expected, no similar enrichment of genes with p53 binding sites in their promoter regions
was observed in U266 cells (data not shown). However, no changes in the expression of p53
transcripts were observed in IM-9 or U266 cells in response to ch128.1Av [Figs. 5(C) and
5(D)]. To determine the contribution of p53 to the cytotoxic effect of ch128.1Av, we
decreased the level of p53 protein expressed by IM-9 cells, via p53-specific siRNA [Fig.
6(A)]. This decrease in p53 expression was consistent with a decrease of approximately 20%
in the inhibition of proliferation induced by ch128.1Av after 24 h of treatment [Fig. 6(B)],
confirming that the toxic effect of iron deprivation induced by ch128.1Av in sensitive cells
is mediated at least in part by the presence of functional p53. A pair of isogenic malignant
lymphoblastoid cell lines, which differ only in their expression of p53 (TK6 expressing wild
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type p53 and NH32 a p53 homozygous mutant at codon 237 of exon 7), also showed
differential sensitivity to treatment with ch128.1Av. TK6 cells showed greater cytotoxicity
at 24 h and 48 h treatment with ch128.1Av than did NH32 cells [Supplementary Figs. 8(A)
and 8(B)], as well as a greater induction of apoptosis [Supplementary Fig. 8(C)]. These
results suggest that toxicity induced by ch128.1Av is in part p53-dependent, and that
functional p53 is required but not sufficient for the cytotoxicity triggered by antibody-
induced iron deprivation.
Discussion
A number of therapeutic antibodies targeting TfR have been designed to exploit the reliance
of hematopoietic malignancies on iron [2,6,9-12,14]. In the present study we further
characterize the molecular events induced by targeting of TfR1 by the non-neutralizing
antibodies ch128.1 and ch128.1Av that contribute to cell death as a result of LID. We
describe the cellular and molecular mechanisms that underlie this antibody-induced LID in a
panel of malignant hematopoietic cells, and identify mechanisms of resistance to ch128.1Av
and potentially other antibodies targeting TfR1.
Sensitivity of cells to antibodies that target TfR1 can be generally attributed to one or more
of the following: antibody neutralization of ligand binding, blocking of receptor
internalization, receptor sequestration/degradation and/or the activation of pro-apoptotic/
anti-proliferative events [6,10,12,14,32]. Resistance, on the other hand, could be attributed
in part to the expression of TfR1 variants, low levels of cell surface expression of TfR1, the
availability of alternative routes of iron import including TfR2, or the aberrant expression of
pro-proliferative/anti-apoptotic molecules that may resist the induction of a cytotoxic
response after iron deprivation is induced [6,10,14,33]. Our present studies indicate that
despite the interaction of resistant malignant cells with ch128.1Av, these cells maintain a
high level of Tf uptake and do not experience a decrease in their intracellular iron stores.
Thus, the possibility that competition might exist between ch128.1Av and Tf only under
certain conditions or with variants of the receptor expressed exclusively by sensitive cells is
unlikely. In addition, no expression of TfR2 or other iron-import proteins was observed in
sensitive or resistant cells (data not shown). Our results suggest that alternative routes of
iron import are not required for resistance in certain cells, since TfR1 remains functional in
resistant cells after treatment with either ch128.1Av or ch128.1. Altogether, our results
suggest that resistance to non-neutralizing antibodies specific for TfR1 stems from the
inability of certain cells to sequester and/or degrade the receptor despite its interaction with
the antibodies. It is possible that these mechanisms of sensitivity and resistance may also
apply to certain neutralizing antibodies. However, these effects are more difficult to study in
the case of neutralizing antibodies given that their cytotoxic activity relies at least in part on
their ability to inhibit the binding of Tf to TfR1 [10,34]. In these cases, one would have to
take into account the changing availability of Tf under physiologically relevant situations,
and the varying density of receptors on target cells.
The mechanisms that facilitate the cytotoxicity of antibodies in vitro, such as the
sequestration and degradation of TfR1 induced by ch128.1Av, may not be as effective in the
complex in vivo environment of growing tumor cells [35]. Likewise, the resistance
mechanisms employed by certain cells may not function in vivo as they would in vitro, and
in some cases, resistant cells may be sensitized by additional or missing factors in vivo.
Varying sensitivities to the inhibition of TfR1 function by ch128.1Av have been observed in
our panel of cell lines in isolates from peritoneal xenografts. Importantly, these results show
a striking similarity to the observed effects of ch128.1Av on TfR1 function in vitro.
Although these experiments may not be an accurate indicator of antibody efficacy in vivo,
they detail the cellular response to TfR1 targeting by antibodies in vivo and the inhibition of
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receptor function up to 2 days after the inoculation of tumor xenografts in a way that is
similar to the mechanisms we observed in vitro. Further studies are needed to determine
whether the inhibition of TfR1 function observed in response to treatment with ch128.1Av,
and to a lesser extent with ch128.1, in sensitive cells in vivo will translate into the induction
of lethal iron deprivation and inhibition of tumor growth.
Our data suggest that the outcome of TfR1 targeting by non-neutralizing antibodies is the
induction of LID. The response of sensitive cells to targeting of TfR1 with antibodies such
as ch128.1Av is similar to that observed with DFO and other iron chelators, an observation
that is supported by changes in the expression of mRNA transcripts in sensitive and resistant
cells after treatment with ch128.1Av. However, the effect of ch128.1Av on transcriptional
regulation of iron-related genes was not as rapid or robust as the previously reported
changes in mRNA transcript expression observed in different cells in response to iron
chelators such as DFO [29], at times as early as 30 min after addition of the iron chelating
agent and up to six-fold higher than control measurements after 20 h [36]. However, despite
the expected slower and less pronounced transcriptional response we have observed after
treatment of sensitive cells (IM-9) with ch128.1Av compared to that previously reported for
pleiotropic chelators, greater selectivity in cell targeting is expected from the use of
therapeutic antibodies to achieve LID [29,30]. Additionally, transcriptional changes induced
in sensitive cells after 24 h treatment with ch128.1Av suggest a role for p53 in the cytotoxic
response to antibody-induced iron deprivation. However, the lack of change in p53
transcripts suggests that only a conversion of latent to active p53 could be responsible for
the effect observed on its downstream targets, instead of de novo synthesis of the protein.
The involvement of p53 or p53-related proteins in the response to iron deprivation in cells
treated with a variety of iron chelating agents has been recently documented [30]. However,
a direct correlation has yet to be established between TfR1 targeting using antibodies and
the activation of p53 target genes. The link between antibody-induced LID and the increased
expression of a significant amount of p53 target genes could exist through the activity of p53
itself and/or other p53-associated proteins and their targets, such as p53R2 [30], given that
ch128.1Av remains cytotoxic to IM-9 cells whose expression of p53 protein has been
reduced using siRNA. In a pair of isogenic cell lines, one expressing wild type p53 (TK6)
and the other an inactive mutant of p53 (NH32), ch128.1Av showed greater selective
cytotoxicity against cells expressing the wild type p53. However, the fact that in cells
expressing both artificially low levels of p53 (after siRNA treatment) and an inactivated
mutant of p53, a cytotoxic effect is still observed after treatment with ch128.1Av, suggests
that this treatment may also be effective against malignancies with defects in p53.
Our data on the inhibition of TfR1 function by ch128.1Av, and to a lesser extent ch128.1, in
a subset of malignant hematopoietic cells support a model of action in which these
antibodies induce LID beginning with the sequestration and/or degradation of TfR1,
followed by the induction of cytotoxic iron deprivation that is mediated in part by
downstream targets of p53. We have found potential avenues of resistance to this approach
to the targeting of TfR1, including the differential regulation of receptor trafficking,
allowing a subset of treated cells to retain normal receptor function and Tf uptake after
treatment, as well as a lack of key molecules that play a role in the cytotoxic response to iron
deprivation, such as functional p53. These resistance mechanisms are not mutually
exclusive, but both can potentially be overcome in future applications through the rational
design of therapies consisting of antibodies targeting TfR1, alone or in combination with
other therapeutic agents. Further studies are still required in a wider variety of cell lines both
in vitro and in vivo to determine the universality of our findings, as well as the limitations of
the present mechanism of TfR1 targeting for the induction of LID. A wide variety of
incurable hematopoietic malignancies, including multiple myeloma and aggressive
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lymphomas, still require adequate therapies and could potentially benefit from the further
development of these treatments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Effect of antibodies targeting human TfR1 on malignant B cells. (A) The rate of
proliferation of cells treated with 10 nM ch128.1Av or 50 μM DFO for 24 or 48 h was
evaluated by [3H]-thymidine incorporation, shown as a percentage of the incorporation
observed in cells treated with buffer alone. Data shown are the average of quadruplicates
and are representative of three independent experiments (*p < 0.05). (B) The percentage of
viability of a panel of cells treated 24 h with buffer as a control (no treatment: NT), 50 μM
DFO, 10 nM ch128.1 or 10 nM ch128.1Av is shown, with error bars indicating standard
deviations (*p < 0.05). (C) Binding of fluorescent Tf to TfR on the cell surface for 1 h at 4
°C of the same panel of cells after pre-incubation for 30 min at 4 °C with 100 nM ch128.1,
100 nM ch128.1Av or buffer as a control (NT), determined by flow cytometry is shown.
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Background fluorescence in the absence of Tf (NL) is shown as a hatched bar. Error bars
indicate standard deviations of fluorescence intensity distributions from flow cytometry
measurements.
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Figure 2.
Effect of antibodies on Tf uptake and internalization of TfR1. (A) Confocal images of cells
incubated with fluorescent Zenon® labeled 10 nM ch128.1, 10 nM ch128.1Av or buffer as a
control for 6 h followed by fluorescent Tf for 30 min at 37 °C. The white bars indicate 20
μm. (B) Quantification of the average internalization of green fluorescent Tf per cell in each
condition and (C) of the average uptake of red fluorescent Zenon® labeled ch128.1 or
ch128.1Av per cell from confocal images at 6 h is shown. Error bars indicate standard
deviations (*p < 0.05).
Rodríguez et al. Page 16
Leuk Lymphoma. Author manuscript; available in PMC 2013 August 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Inhibition of TfR1 function in vivo in a panel of malignant hematopoietic cells. Cells labeled
with CMPTX® red, injected in the peritoneal cavity of SCID-Beige mice in the presence of
buffer as a control (NT), 50 μg ch128.1 or 50 μg ch128.1Av for 48 h were recovered, and
exposed to a pulse of green fluorescent Tf for 30 min at 37 °C, with buffer treated un-
injected (UI) cells shown as controls. The quantification of fluorescent Tf uptake analyzed
by flow cytometry from both un-injected and those recovered 48 h post-injection is shown.
Error bars indicate standard deviations (*p < 0.05).
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Figure 4.
Antibody-induced TfR1 degradation in vitro. (A) Whole-cell levels of TfR1 in a panel of
malignant B cells after 12 h treatment with buffer as a control (NT), ch128.1 or ch128.1Av.
(B) Quantification of whole-cell levels of TfR1 after 12 h treatment with buffer as a control
(NT), ch128.1 or ch128.1Av. The ratio of TfR1, detected from a compilation of 3
independent experiments with respect to the level of GAPDH is shown, with all treatments
compared to buffer treated cells. Error bars indicate standard deviations (*p < 0.05).
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Figure 5.
Transcriptional changes in IM-9 and U266 cells treated with ch128.1Av. (A) Expression
profiles of U266 (left) and IM-9 (right) cells treated with 10 nM ch128.1Av sampled at 1 h,
3 h, 9 h and 24 h compared to their time-matched controls are shown. Hierarchical clustering
of genes and treatment times is based on their expression changes, as determined by an un-
centered correlation algorithm. Genes shown are those with the greatest time-dependent
variance in ch128.1Av treated IM-9 and U266 cells compared to their time-matched controls
(p < 0.05). The color bar shows fold changes from low (blue) to high (red) expression with
respect to controls on a log base 2 scale; gene names and descriptions are listed in
Supplementary Table I. (B) Heat map of differentially expressed IRE-containing genes in
U266 (left) and IM-9 (right) cells at 1 h, 3 h, 9 h and 24 h compared to time-matched
controls. The accompanying color bar indicates fold changes from low (green) to high (red)
expression with respect to controls on a log base 2 scale. (C, D) Quantitative RT-PCR
validation of select differentially expressed genes from panel A in U266 (C) and IM-9 (D)
cells treated with 10 nM ch128.1Av compared to time-matched controls at 1 h and 24 h; fold
changes are shown on a log base 2 scale.
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Figure 6.
The role of p53 in antibody-induced LID. (A) An immunoblot of p53 expression in IM-9
cells 24 h after electroporation with a non-specific siRNA or p53-targeted siRNA; GAPDH
is shown as a loading control. (B) [3H]-thymidine incorporation of cells with and without
siRNA-mediated reduction of p53 expression treated with 10 nM ch128.1Av for 48 h or 24
h after electroporation. Data is shown as a percent of control treated cells, with error bars
indicating standard deviations of triplicate samples (*p < 0.05). Immunoblot and
proliferation assay data were obtained from the same experiment.
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